Drug intelligence / Profile preview

ZB006

Development stage: Preclinical
Lead developer: Zenas BioPharma
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

**ZB006** is a monoclonal antibody classified as an immunomodulator, developed initially by Dianthus Therapeutics, Inc., with China rights licensed to Zenas BioPharma. It targets immune pathways for the treatment of **autoimmune diseases** within the therapeutic area of immune system diseases. The drug is currently in **preclinical development**, representing one of Zenas' pipeline assets aimed at addressing unmet needs in immunology through antibody-based modulation.[1][7][9]

Beyond the preview

Go deeper on ZB006.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ZB006.

Explore the full profile